Martin Tolar

Company: Alzheon

Job title: Founder, President & Chief Executive Officer

Seminars:

ALZ-801 Phase 3 Program: Lessons & The Path Forward in Developing Targeted Therapies for Alzheimer’s Disease 3:30 pm

Highlighting the benefits of applying genomic stratification of patients for validation of biomarkers from target discovery to therapeutic development Describing discovery of a novel molecular mechanism of action of ALZ- 801, which blocks formation of toxic amyloid oligomers associated with development and progression of Alzheimer’s disease Reviewing development of ALZ-801, a Phase 3, first-in-class, small…Read more

day: Day One